Leef Brands (LEEEF) Debt to Equity (2023 - 2026)

Leef Brands' (LEEEF) quarterly Debt to Equity came in at -$1.7 in Q1 2026, down 38.79% quarter-over-quarter from -$1.22 in Q4 2025.

Leef Brands (LEEEF) Debt to Equity (2023 - 2026) Analysis & Trends

Leef Brands has disclosed Debt to Equity across 4 years of filings, most recently posting -$1.7 for Q1 2026.

  • Debt to Equity for Q1 2026 came in at -$1.7, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.7 (changed N/A YoY), and the FY2025 annual result was -$1.22, down 56.19% from the prior year.
  • Debt to Equity came in at -$1.7 for Q1 2026 at Leef Brands, down from -$1.22 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $9.51 in Q4 2023 to a low of -$1.7 in Q1 2026.
  • The 4-year median for Debt to Equity is -$1.0 (2024), against an average of $1.45.
  • Across the five-year window, Debt to Equity slumped 108.24% in 2024 and sank 56.19% in 2025, its largest moves.
  • Leef Brands' Debt to Equity stood at $9.51 in 2023, then plunged by 108.24% to -$0.78 in 2024, then slumped by 56.19% to -$1.22 in 2025, then sank by 38.79% to -$1.7 in 2026.
  • The last three Debt to Equity figures came in at -$1.7 (Q1 2026), -$1.22 (Q4 2025), and -$0.78 (Q4 2024), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt/Equity (Qtr)
1 Teva Pharmaceutical Industries 39.72 Bn 35.98 Bn 1.97 Bn 2.02
2 Zoetis 34.61 Bn 32.67 Bn 1.62 Bn 2.80
3 United Therapeutics 24.07 Bn 21.91 Bn 648.10 Mn -
4 Aurora Cannabis 16.98 Bn 16.91 Bn 33.43 Mn 0.01
5 Neurocrine Biosciences 16.64 Bn 15.32 Bn 800.70 Mn -
6 Elanco Animal Health 12.19 Bn 11.76 Bn 785.00 Mn 0.61
7 Alkermes 7.37 Bn 6.86 Bn -116.06 Mn 0.86
8 Hims & Hers Health 6.62 Bn 5.87 Bn 396.79 Mn -
9 Lantheus Holdings 6.47 Bn 5.97 Bn 230.92 Mn 0.47
10 Leef Brands - - 4.62 Mn -1.70

Historic Data

Download Data
DateValue
Mar 31, 2026 -1.70
Dec 31, 2025 -1.22
Dec 31, 2024 -0.78
Dec 31, 2023 9.51